Corium, Inc. Announces FDA Filing Acceptance of New Drug Application for ADLARITY® (donepezil transdermal system) for the Treatment of Alzheimer’s Disease
January 27, 2020 08:30 ET
|
Corium International, Inc.
MENLO PARK, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Corium, Inc., a commercial-stage biopharmaceutical company leading the development of novel transdermal healthcare products that are intended to...
Corium Appoints Perry Sternberg as Chief Executive Officer
April 02, 2019 16:30 ET
|
Corium International, Inc.
MENLO PARK, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Corium, Inc. announced today that its Board of Directors has named Perry Sternberg as Chief Executive Officer. Mr. Sternberg is a senior...
Corium Announces Offer to Purchase for Cash Any and All of the $120,000,000 Aggregate Outstanding Principal Amount of 5.00% Convertible Senior Notes due 2025
December 17, 2018 09:30 ET
|
Corium International, Inc.
MENLO PARK, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc., a Delaware corporation (“Corium”, the “Issuer”, “we”, “us” or “our”), today announced that, as a result of its...
Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares
October 11, 2018 16:03 ET
|
Corium International, Inc.
Total Transaction Valued in Excess of $500 Million, Representing a 50% Premium Gurnet Point Capital to Expand Operations While Focusing on the Approval and Commercialization of Corium’s Corplex...
Corium to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
September 24, 2018 07:30 ET
|
Corium International, Inc.
MENLO PARK, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and...
Corium to Present at the H. C. Wainwright 20th Annual Global Investment Conference
August 29, 2018 07:30 ET
|
Corium International, Inc.
MENLO PARK, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and...
Corium Reports Third Quarter Fiscal 2018 Financial Results and Corporate Highlights
August 09, 2018 16:01 ET
|
Corium International, Inc.
MENLO PARK, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and...
Corium to Report Third Quarter Fiscal 2018 Financial Results on Thursday, August 9, 2018
August 02, 2018 07:30 ET
|
Corium International, Inc.
MENLO PARK, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ: CORI) today announced that it will report financial results for the third quarter ended June 30, 2018 on...
Corium Presents Additional Positive Clinical Results at Alzheimer's Association International Conference® 2018
July 25, 2018 10:30 ET
|
Corium International, Inc.
MENLO PARK, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and...
Corium Announces Issuance of Additional U.S. Patent Covering Corplex™ Donepezil Transdermal System for Alzheimer’s Disease
July 11, 2018 07:30 ET
|
Corium International, Inc.
MENLO PARK, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ:CORI), a commercial stage biopharmaceutical company focused on the development, manufacture and...